🇺🇸 FDA
Patent

US 10611851

Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins

granted A61PA61P31/04

Quick answer

US patent 10611851 (Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins) held by The Regents of the University of California expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61P, A61P31/04